STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable <i>BRAF</i> V600-mutant melanoma.

Schadendorf, Dirk; Dummer, Reinhard; Robert, Caroline; Ribas, Antoni; Sullivan, Ryan J; Panella, Timothy; McKean, Meredith; Santos, Edgardo S; Brill, Kimberli; Polli, Anna; Pietro, Alessandra di; Ascierto, Paolo A

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.

Schadendorf, Dirk; Dummer, Reinhard; Robert, Caroline; Ribas, Antoni; Sullivan, Ryan J; Panella, Timothy; McKean, Meredith; Santos, Edgardo S; Brill, Kimberli; Polli, Anna; Pietro, Alessandra di; Ascierto, Paolo A.

Afiliação

Schadendorf D; Department of Dermatology, University Hospital Essen, 45122 Essen, Germany & German Cancer Consortium, Partner Site Essen, Germany.
Dummer R; Department of Dermatology, University Hospital Zürich & University Zurich, Zurich, 8091, Switzerland.
Robert C; Melanoma Research Unit, Institut Gustave Roussy, Villejuif, 94805, France.
Ribas A; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Sullivan RJ; Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115 USA.
Panella T; Department of Medicine, Division of Hematology & Oncology, University of Tennessee, Knoxville, TN 37996, USA.
McKean M; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN 37203, USA.
Santos ES; Florida Precision Oncology/A Division of Genesis Care USA, Florida Atlantic University, Aventura, FL 33180, USA.
Brill K; Pfizer, La Jolla, CA 92037, USA.
Polli A; Pfizer S.R.L., Milan, 20152, Italy.
Pietro AD; Pfizer, La Jolla, CA 92037, USA.
Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, 80131, Italy.

Future Oncol ; 18(17): 2041-2051, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35272485

Targeted therapy, including BRAF- and MEK-inhibitors, and immunotherapies have greatly contributed to advances in the treatment of BRAF-mutant melanoma. Additionally, immunotherapy in combination with targeted therapy has been shown to improve patient outcomes. In this study, the authors assess the efficacy and safety of a combination of a BRAF-inhibitor (encorafenib), an MEK-inhibitor (binimetinib) and an anti-PD-1 (pembrolizumab) in patients with metastatic BRAF-mutant melanoma. Clinical Trial Registration: NCT04657991 (ClinicalTrials.gov).

Assuntos

Melanoma; Segunda Neoplasia Primária; Neoplasias Cutâneas; Anticorpos Monoclonais Humanizados; Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos; Benzimidazóis; Carbamatos; Humanos; Melanoma/tratamento farmacológico; Melanoma/genética; Mutação; Segunda Neoplasia Primária/etiologia; Inibidores de Proteínas Quinases/uso terapêutico; Proteínas Proto-Oncogênicas B-raf/genética; Ensaios Clínicos Controlados Aleatórios como Assunto; Neoplasias Cutâneas/tratamento farmacológico; Neoplasias Cutâneas/genética; Sulfonamidas

Palavras-chave

BRAF V600 mutations; advanced melanoma; binimetinib; encorafenib; immunotherapy; pembrolizumab; targeted therapy; triplet combination therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Segunda Neoplasia Primária / Melanoma Tipo de estudo: Clinical_trials / Etiology_studies / Guideline Limite: Humans Idioma: En Revista: Future Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google